The conclusion that there was nothing wrong with the specifics of the TeGenero trial in which six healthy volunteers ended up in intensive care has repercussions for the wider biotech industry.
Chroma Therapeutics Ltd raised £30 million in a third private round, giving the chromatin specialist funding for the next three years and enabling it to advance the lead programme through Phase II clinical studies and bring two further products into the clinic.
Lots of buzz preceded what was billed as the world's first live, multi-lot technology patent auction on April 6, but reality failed to meet expectations for many of the inventors who put up 400-plus patents for sale.
After finding nothing wrong with the specifics of the preclinical data, the product, or how the trial was conducted, the UK Medicines and Healthcare Products Regulatory Agency has ordered an investigation to changes in clinical trials procedures.
A spin-out from Helsinki University of Technology is looking for further funding and possible partnerships to jointly develop and commercialise its thin flexible paper battery technology.
A Chicago merchant bank will take a new twist on selling intellectual property next week when it holds a live auction to sell 400-plus patents from some of the most valued technology innovators in the world. Lori Valigra looks at the list.
Sweden is ranked number one among 31 European nations for its spending on R&D - but it is still looking for its first home-grown biotechnology product.
Tectonic shifts in the patent landscape could follow on from high-profile lawsuits challenging what can be protected by a patent and how patents are enforced that are due to be heard by the US Supreme Court this month.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.